- Home
- / Cartesian Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cartesian Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$22.4
2024-10-29
Market Capitalization
$536.3 M
2024-10-29
Revenue
$38.9 M
FY, 2024
CreditSafe Score
?
Score changed on Jul 08, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.1M | 6.7M | 16.6M | 85.1M | 110.8M | 26.0M | 38.9M |
| General and administrative expense | 13.1M | 16.4M | 18.9M | 20.9M | 23.9M | 40.6M | 30.1M |
| Operating expense total | 42.8M | 59.1M | 73.4M | 96.2M | 75.2M | ||
| EBIT | (34.7M) | (52.5M) | (56.8M) | (4.6M) | 14.5M | (86.4M) | (43.9M) |
| EBIT margin, % | -428.9% | -785.6% | -342.4% | 13.1% | -112.8% | ||
| Investment income | 234.0K | 834.0K | 260.0K | 44.0K | 2.1M | 5.0M | |
| Interest income | 7.4M | ||||||
| Interest expense | 2.8M | ||||||
| Pre tax profit | (9.7M) | 34.8M | (238.7M) | (77.1M) | |||
| Income tax expense | 16.0M | (609.0K) | (19.0M) | 287.0K | |||
| Net Income | (36.2M) | (55.3M) | (68.9M) | (25.7M) | 35.4M | (219.7M) | (77.4M) |
| EPS | 0.1 | (1.0) | (4.5) |